Drug Profile
MK 2295
Alternative Names: MK-2295; NGD-8243Latest Information Update: 30 Dec 2014
Price :
$50
*
At a glance
- Originator Merck & Co; Neurogen Corporation
- Developer Merck & Co
- Class Analgesics; Small molecules
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 05 Jun 2007 Phase-II development is ongoing
- 01 Nov 2006 Phase-II clinical trials in Pain in USA (PO) (NCT00387140)